Company:  DENALI THERAPEUTICS INC. (DNLI)
Form Type:  S-1/A
Filing Date:  12/7/2017 
CIK:  0001714899 
Address:  151 OYSTER POINT BLVD.
2ND FLOOR
 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 866-8548 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$20.99  
Change: 
-0.46 (-2.15%)  
Trade Time: 
Dec 11  
Market Cap: 
$1.85B
Trade DNLI now with 

© 2017  
Description of Business
Neurodegeneration represents one of the most significant unmet medical needs of our time, with few effective therapeutic options available for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, or ALS, and other neurodegenerative diseases. The burden of these diseases to patients and society is massive. We believe the time is right to make a strong and ambitious effort to defeat neurodegeneration. We believe that we can succeed in a field that has seen limited success in the past, because of our team of experienced and passionately dedicated scientists and drug developers, our focused scientific strategy, and our proprietary blood-brain barrier, or BBB, platform delivery technology. We are developing a broad portfolio of targeted therapeutic candidates for neurodegenerative diseases and have recently initiated our first clinical trials. We commenced operations in May 2015.
Register and access this filing in:     
  FORM S-1/A
    CALCULATION OF REGISTRATION FEE
    SUBJECT TO COMPLETION. DATED DECEMBER 7, 2017
    TABLE OF CONTENTS
    PROSPECTUS SUMMARY
    THE OFFERING
    SUMMARY CONSOLIDATED FINANCIAL DATA
    RISK FACTORS
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    DIVIDEND POLICY
    CAPITALIZATION
    DILUTION
      BENEFICIAL OWNERS
    SELECTED CONSOLIDATED FINANCIAL DATA
    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
      Operating Expenses
      Liquidity and Capital Resources
      Quantitative and Qualitative Disclosures About Market Risk
    BUSINESS
      Competition
      Employees
      Legal Proceedings
    MANAGEMENT
      NAME AND TITLE
    Director Compensation
    EXECUTIVE COMPENSATION
      COMPENSATION TABLE
      Employee Benefit and Stock Plans
    CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
    PRINCIPAL STOCKHOLDERS
      BENEFICIAL OWNERS
    DESCRIPTION OF CAPITAL STOCK
    Transfer Agent and Registrar
    SHARES ELIGIBLE FOR FUTURE SALE
    MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS ...
    UNDERWRITING
    LEGAL MATTERS
    EXPERTS
    WHERE YOU CAN FIND ADDITIONAL INFORMATION
    INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
      Notes to Consolidated Financial Statements
      Indemnification
      OPTIONS
    Performance and Market Contingent Stock Options Granted to ...
    PART II
      Item 13. Other Expenses of Issuance and Distribution
      Item 14. Indemnification of Directors and Officers
      Item 15. Recent Sales of Unregistered Securities
      Item 16. Exhibit and Financial Statement Schedules
      Item 17. Undertakings
    SIGNATURES
  EXHIBIT 3.1.1
    CERTIFICATE OF INCORPORATION
  EXHIBIT 5.1
  EXHIBIT 10.4
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM